These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
332 related articles for article (PubMed ID: 8548416)
1. Plasma concentration of apolipoprotein E in intermediate-sized remnant-like lipoproteins in normolipidemic and hyperlipidemic subjects. Cohn JS; Tremblay M; Amiot M; Bouthillier D; Roy M; Genest J; Davignon J Arterioscler Thromb Vasc Biol; 1996 Jan; 16(1):149-59. PubMed ID: 8548416 [TBL] [Abstract][Full Text] [Related]
2. Plasma lipoprotein distribution of apoC-III in normolipidemic and hypertriglyceridemic subjects: comparison of the apoC-III to apoE ratio in different lipoprotein fractions. Fredenrich A; Giroux LM; Tremblay M; Krimbou L; Davignon J; Cohn JS J Lipid Res; 1997 Jul; 38(7):1421-32. PubMed ID: 9254067 [TBL] [Abstract][Full Text] [Related]
3. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins. Marcoux C; Tremblay M; Fredenrich A; Davignon J; Cohn JS Metabolism; 2001 Jan; 50(1):112-9. PubMed ID: 11172484 [TBL] [Abstract][Full Text] [Related]
4. Characterization of remnant-like particles isolated by immunoaffinity gel from the plasma of type III and type IV hyperlipoproteinemic patients. Marcoux C; Tremblay M; Nakajima K; Davignon J; Cohn JS J Lipid Res; 1999 Apr; 40(4):636-47. PubMed ID: 10191287 [TBL] [Abstract][Full Text] [Related]
5. Plasma remnant-like particle lipid and apolipoprotein levels in normolipidemic and hyperlipidemic subjects. Marcoux C; Tremblay M; Fredenrich A; Jacques H; Krimbou L; Nakajima K; Davignon J; Cohn JS Atherosclerosis; 1998 Jul; 139(1):161-71. PubMed ID: 9699904 [TBL] [Abstract][Full Text] [Related]
6. Quantitation of human apolipoprotein C-III and its subspecie by radioimmunoassay and analytical isoelectric focusing: abnormal plasma triglyceride-rich lipoprotein apolipoprotein C-III subspecie concentrations in hypertriglyceridemia. Kashyap ML; Srivastava LS; Hynd BA; Gartside PS; Perisutti G J Lipid Res; 1981 Jul; 22(5):800-10. PubMed ID: 7288286 [TBL] [Abstract][Full Text] [Related]
7. Effects of nicotinic acid therapy on plasma lipoproteins and very low density lipoprotein apoprotein C subspecies in hyperlipoproteinemia. Yovos JG; Patel ST; Falko JM; Newman HA; Hill DS J Clin Endocrinol Metab; 1982 Jun; 54(6):1210-5. PubMed ID: 7076797 [TBL] [Abstract][Full Text] [Related]
8. Differences in the lipoprotein distribution of halofantrine are regulated by lipoprotein apolar lipid and protein concentration and lipid transfer protein I activity: in vitro studies in normolipidemic and dyslipidemic human plasmas. Wasan KM; Ramaswamy M; McIntosh MP; Porter CJ; Charman WN J Pharm Sci; 1999 Feb; 88(2):185-90. PubMed ID: 9950636 [TBL] [Abstract][Full Text] [Related]
9. Genetic factors precipitating type III hyperlipoproteinemia in hypolipidemic transgenic mice expressing human apolipoprotein E2. Huang Y; Rall SC; Mahley RW Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2817-24. PubMed ID: 9409260 [TBL] [Abstract][Full Text] [Related]
10. Structural peculiarities of the binding of very low density lipoproteins and low density lipoproteins to the LDL receptor in hypertriglyceridemia: role of apolipoprotein E. Dergunov AD; Smirnova EA; Merched A; Visvikis S; Siest G; Yakushkin VV; Tsibulsky V Biochim Biophys Acta; 2000 Feb; 1484(1):29-40. PubMed ID: 10685028 [TBL] [Abstract][Full Text] [Related]
11. Fish oil supplementation reduces beta-very low density lipoprotein in type III dysbetalipoproteinemia. Dallongeville J; Boulet L; Davignon J; Lussier-Cacan S Arterioscler Thromb; 1991; 11(4):864-71. PubMed ID: 2065040 [TBL] [Abstract][Full Text] [Related]
12. Accumulation of an apoE-poor subfraction of very low density lipoprotein in hypertriglyceridemic men. Evans AJ; Huff MW; Wolfe BM J Lipid Res; 1989 Nov; 30(11):1691-701. PubMed ID: 2614271 [TBL] [Abstract][Full Text] [Related]
13. Abnormal in vivo metabolism of apolipoprotein E4 in humans. Gregg RE; Zech LA; Schaefer EJ; Stark D; Wilson D; Brewer HB J Clin Invest; 1986 Sep; 78(3):815-21. PubMed ID: 3745440 [TBL] [Abstract][Full Text] [Related]
14. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages. Milosavljevic D; Griglio S; Le Naour G; Chapman MJ Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449 [TBL] [Abstract][Full Text] [Related]
15. Enrichment of Triglyceride-Rich Lipoproteins with Apolipoprotein C-I Is Positively Associated with Their Delayed Plasma Clearance Independently of Other Transferable Apolipoproteins in Postmenopausal Overweight and Obese Women. Wassef H; Bissonnette S; Dufour R; Davignon J; Faraj M J Nutr; 2017 May; 147(5):754-762. PubMed ID: 28356429 [No Abstract] [Full Text] [Related]
16. Recent progress in the development of radioimmunoassays for human serum lipoproteins. Karlin JB; Juhn DJ; Goldberg R; Rubenstein AH Ann Clin Lab Sci; 1978; 8(2):142-54. PubMed ID: 205163 [TBL] [Abstract][Full Text] [Related]
17. Triglyceride-rich lipoprotein, remnant cholesterol, and apolipoproteins CII, CIII, and E in patients with schizophrenia. Wang J; Kockx M; Bolek M; Lambert T; Sullivan D; Chow V; Kritharides L J Lipid Res; 2024 Jul; 65(7):100577. PubMed ID: 38879166 [TBL] [Abstract][Full Text] [Related]
18. Effect of heparin-induced lipolysis on the distribution of apolipoprotein e among lipoprotein subclasses. Studies with patients deficient in hepatic triglyceride lipase and lipoprotein lipase. Rubinstein A; Gibson JC; Paterniti JR; Kakis G; Little A; Ginsberg HN; Brown WV J Clin Invest; 1985 Feb; 75(2):710-21. PubMed ID: 3973025 [TBL] [Abstract][Full Text] [Related]
19. Association of Lp(a) rather than integrally-bound apo(a) with triglyceride-rich lipoproteins of human subjects. Marcoux C; Lussier-Cacan S; Davignon J; Cohn JS Biochim Biophys Acta; 1997 Jun; 1346(3):261-74. PubMed ID: 9219911 [TBL] [Abstract][Full Text] [Related]
20. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux. Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]